Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px
Document › Details

Evotec AG. (10/20/11). "Press Release: Evotec and Apeiron Biologics Start Next Project on the Cbl-b Target". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Group Evotec (Group)
  Organisation 2 Apeiron Biologics AG
  Group Apeiron (Group)
Products Product drug discovery services
  Product 2 cancer drug
Index term Index term Apeiron–Evotec: drug discovery services, 201110– collab €na identification of molecules targeting Cbl-b for anti-tumor immune therapy
Persons Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
  Person 2 Loibner, Hans (Apeiron Biologics 200810–201807 CEO RETIRED 7/18 continues as senior advisor)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.

Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enhance anti-tumor activities both for tumor antigen-specific cells and for those recognizing general features of tumor cells.

Evotec will apply their skills and proprietary technologies in cellular assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with Cbl-b. The aim of the collaboration will be to take compounds identified by Evotec as being active against this target or other relevant targets and further jointly optimize them as basis for formal preclinical and clinical development.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are very pleased to start a new project with Apeiron. It is strategically important to be involved in high promising early stage biotech projects."

Dr Hans Loibner, Chief Executive Officer at Apeiron Biologics, commented: "Apeiron's substantial expertise in applied immunology and cancer immunotherapy plus Evotec's remarkable skills in high-throughput methodology are an excellent basis for the successful identification and development of novel drugs that enhance the power of the immune system to combat cancer. This growing area has major clinical and commercial potential. "

No financial details are disclosed.


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating stateof-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and with Andromeda (Teva) in the field of diabetes. For additional information please go to


Apeiron is a privately financed biotech company based in Vienna, Austria. Apeiron focuses on biological and immunological treatments of cancer. Apeiron's project portfolio consists of five projects in clinical evaluation and four preclinical projects. Clinical projects include two antibody-based therapies against high-risk neuroblastoma in Phase II and III (APN301 and APN311). Also in clinical stage is a liposomal formulation of recombinant human Superoxide Dismutase (APN201) to prevent or treat skin damage due to radiation treatment in cancer. A further clinical project, recombinant human Angiotensin Converting Enzyme 2 (APN01), was licensed to GlaxoSmithKline early 2010. It is expected to commence a Phase II study for the treatment of Acute Respiratory Distress Syndrome in the near future and has considerable potential in other disease areas. A unique customized cellular cancer immunotherapy based on ex-vivo silencing of immune cells also utilizes the Cblb target and is close to Phase I (APN401). Apeiron is operational since 2006 and presently employs 25 people.

Forward-Looking Statements - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Evotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px

» top